EyePoint, Inc.'s SEC filings document its business as a clinical-stage retinal-disease therapeutics company and record formal disclosures around DURAVYU, its investigational vorolanib intravitreal insert using Durasert E sustained-delivery technology. Form 8-K reports cover operating results, financial condition, cash resources, clinical-development updates for wet AMD and DME, investor presentations, and other material company events.
The company's proxy materials disclose governance, executive compensation, equity awards, shareholder voting matters, and board-related information. Additional filings record Nasdaq-listed common stock information, Regulation FD disclosures, forward-looking risk language, and legal-proceeding disclosures related to public statements about DURAVYU and its clinical results.
EyePoint, Inc. filed a current report to let investors know it has released a press release with preliminary cash information as of December 31, 2025 and other corporate updates. The company notes that these figures are preliminary, unaudited and may change once full audited financial statements for the year are completed. The press release is included as Exhibit 99.1, allowing the disclosed preliminary cash position and corporate developments to be incorporated by reference in future securities offerings or other SEC filings.
EyePoint, Inc. Chief Financial Officer Elston George reported multiple equity compensation transactions and related share issuances and tax withholdings in early January 2026. On January 2, 2026, he received 63,000 restricted stock units and a stock option for 126,000 shares, both at an exercise or conversion price of $0.00, with the RSUs vesting in three annual installments beginning January 2, 2027 and the option vesting 25% on January 2, 2027 and the remainder monthly over three years. On January 3 and 5, 2026, previously granted RSUs vested and converted into a total of 34,667 shares of common stock, with 6,324 and 4,403 shares withheld at prices of $17.48 and $17.43 to satisfy tax obligations, and no shares sold into the market. Following these transactions, he directly held 81,054 shares of common stock and derivative awards, and an additional 25,000 shares are held indirectly by a family trust for his children, for which he disclaims beneficial ownership.
EyePoint, Inc. director Reginald J. Sanders reported a grant of stock options. On January 2, 2026, he received 40,000 stock options with an exercise price of $17.48 per share. These options become exercisable on January 2, 2027 and expire on January 2, 2036, and each option corresponds to one share of common stock. Following this grant, Sanders beneficially owns 40,000 derivative securities, held in direct ownership.
EyePoint, Inc. director Nancy Lurker reported equity awards and updated share holdings. On January 2, 2026, she was granted a stock option to buy 40,000 shares of common stock at $17.48, exercisable starting January 2, 2027 and expiring January 2, 2036. On January 5, 2026, 12,666 restricted stock units were converted into the same number of common shares at $0.00 per share, leaving her with 219,213 shares of common stock held directly and 12,667 restricted stock units outstanding. Separately, 126,889 shares of common stock are held indirectly through a family trust for her children, with her spouse as trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. director Duty Stuart reported a grant of stock options in a Form 4 filing. On January 2, 2026, Stuart received a stock option (right to buy) covering 40,000 shares of EyePoint common stock at a conversion or exercise price of $17.48 per share. The option is first exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Stuart beneficially owned 40,000 derivative securities related to EyePoint common stock, held in direct ownership form.
EyePoint Pharmaceuticals reported that an independent Data Safety Monitoring Committee issued a positive recommendation after completing its second scheduled safety review of the company’s ongoing pivotal Phase 3 program of DURAVYU™ for treating wet age-related macular degeneration (wet AMD). This means the committee saw no safety concerns that would require changing or stopping the trial, so the late-stage study is continuing as planned. The update highlights steady progress of DURAVYU in a key registration-directed program aimed at a major retinal disease that can lead to vision loss.
EyePoint Pharmaceuticals (EYPT) reported an insider transaction by its Chief Medical Officer. On 11/11/2025, the officer sold 2,722 shares of common stock in open market transactions at a weighted average price of $11.61. The filing states these shares were originally acquired on January 31, 2025 under the company’s 2019 Employee Stock Purchase Plan. Following the sale, the filing lists 0.00 shares beneficially owned, reported as Direct (D) ownership.
EyePoint Pharmaceuticals filed a prospectus supplement covering the registered offering of up to $200,000,000 of common stock pursuant to its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. The supplement relates to the company’s effective Form S-3 (File No. 333-290867), which became automatically effective upon filing.
The company also filed a legal opinion from Hogan Lovells US LLP validating the Shares, included as Exhibit 5.1. This filing provides a framework to sell shares as needed under the existing sales agreement, offering flexibility to access capital subject to market conditions.
EyePoint Pharmaceuticals (EYPT) launched an at-the-market offering of up to $200,000,000 in common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. Shares may be sold from time to time in transactions deemed “at the market offerings” under Rule 415(a)(4), including sales on The Nasdaq Global Market. Cantor will act as sales agent and receive a fixed commission equal to 3.0% of the aggregate gross sales price per share sold.
The company states it intends to use net proceeds to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs leveraging its Durasert E technology, and for general corporate purposes. The common stock trades on Nasdaq under “EYPT”; the last reported sale price was $12.45 on November 3, 2025.
EyePoint Pharmaceuticals (EYPT) reported a wider Q3 loss as it advances late‑stage trials. Total revenue was $0.97 million, down 91% year over year, mainly due to prior deferral recognition tied to YUTIQ® licensing. Research and development rose to $47.8 million (up 62%) as Phase 3 wet AMD studies (LUGANO, LUCIA) continued. Net loss was $59.7 million, or $0.85 per share.
Cash, cash equivalents and marketable securities were $204.0 million as of September 30, 2025. After quarter‑end, the company closed an underwritten equity offering with net proceeds of approximately $162.1 million and sold additional shares via its ATM. Management states these resources are expected to fund operations into the fourth quarter of 2027, beyond anticipated 2026 topline data for DURAVYU™.
Deferred revenue from the ANI YUTIQ® arrangement was fully recognized by Q2 2025, reducing current‑period license revenue. The company recorded a $4.7 million accrual for a potential DOJ matter resolution. Shares outstanding were 82,787,220 as of October 30, 2025.